@FiercePharma: Top-read on FP Tuesday: J&J's powerhouse drug launches drive 21% boost to Q2 pharma sales. Story | Follow @FiercePharma
@EricPFierce: GSK investing $25M in Codexis technology as it looks for 'more elegant' ways to manufacture APIs. FiercePharmaManufacturing story | Follow @EricPFierce
@CarlyHFierce: Merck is aiming to revive Zilmax sales, but it's not that easy after safety scare. Article | Follow @CarlyHFierce
> Bristol-Myers Squibb ($BMY) asked a U.S. Circuit Court to convene en banc to rehear its case for a patent on the hepatitis B drug Baraclude. More
> Impax Laboratories ($IPXL) said it received a subpoena Monday in a Connecticut probe of potential price-fixing on digoxin, a generic heart drug. Story
> Nine children fed with a Teva ($TEVA) parenteral nutrition product were hospitalized with blood infections; production of the solution has been halted temporarily. Release
> India's Sun Pharmaceutical Industries said Wednesday that it had acquired U.S.-based Pharmalucence. Release
> Hikma Pharmaceuticals announced it had completed its $225 million-plus acquisition of Bedford Laboratories from Ben Venue Laboratories. Details
Medical Device News
@FierceMedDev: Boston Scientific wins expanded European approval for Lotus transcatheter valve system. Article | Follow @FierceMedDev
@MichaelGFierce: Delivering breast cancer drug through the skin grants disease prevention. FierceDrugDelivery story | Follow @MichaelGFierce
@EmilyWFierce: Placenta plays vital role in fetal development, but much remains in the way of medical breakthroughs and research. More from the NYT | Follow @EmilyWFierce
> St. Jude Medical charts positive Q2 numbers, thanks in part to recent M&A. Article
> Medtronic's Hospital of the Future akin to birthing an elephant. Story
Biotech News
@FierceBiotech: ICYMI yesterday: Three more biotechs target $175M in IPO cash amid market tumult. Report | Follow @FierceBiotech
@DamianFierce: A+ photo choice. It's like he's snatching the savings right outta your hand. More from the WSJ | Follow @DamianFierce
@EmilyMFierce: ICYMI yesterday, check out the latest issue of FierceBiotech Research. Report | Follow @EmilyMFierce
> Roche is at an Alzheimer's crossroads after mixed data for AC Immune's drug. Story
> 'Economic patriotism' could dampen biopharma's M&A boom. Article
> Cancer vaccine maker immatics adds nearly $30M in Series D. News
> GlaxoSmithKline and Theravance eye Phase III for another COPD contender. Article
> Immunocore and Lilly strike a risk-sharing deal in oncology R&D. News
Drug Delivery News
> Boston Scientific wins CE mark for 25-mm drug-eluting Lotus Transcatheter Aortic Valve. Item
> UPenn researchers develop nanogel for mitigating lung inflammation. Report
> Nanoliposome vehicles bring second-wave treatment for metastatic pancreatic cancer. More
> Delivering breast cancer drug through the skin grants disease prevention. Article
> Nasal version of naloxone for opioid overdose gets on FDA's fast track. Story
Diagnostics News
> Asuragen gains New York state's OK to launch autism and thyroid tests. More
> Roche and Merck KGaA team on a multicancer companion diagnostic test. Story
> MGC Diagnostics grows international reach with Belgian M&A deal. News
> NeuroVision Imaging's CEO discloses approval timeline for eye test to help spot Alzheimer's. Report
> Maryland researchers expand usefulness of schizophrenia biomarker found in saliva. Article
Pharma Marketing News
> J&J's new hep C med Olysio aced Q2. So why are investors worried? More
> Orphan drug approvals are up, but prices are up more. Report
> Afraid of aging? Pfizer's revamped 'Get old' campaign wants you. Story
> In social media, what's easier to grasp--an FDA webinar or an FDA warning letter? More
> Roche's Avastin steps on FDA fast track for new cervical cancer use. Article
And Finally... Rates of first-time strokes and stroke-related death have plunged in the U.S., a JAMA study revealed. Article